Loading
Adding the old blood-vessel antibody to a late-line chemotherapy pill extended survival by three months in patients who had exhausted standard options.
SUNLIGHT, trial NCT04737187 sponsored by Taiho and Servier and reported in 2023, showed that adding the old anti-VEGF antibody bevacizumab to the late-line chemotherapy tablet trifluridine and tipiracil extends survival by a few months in refractory metastatic colorectal cancer. It randomised 492 patients and met its primary overall survival endpoint, leading to FDA approval in August 2023 and making the combination the preferred third-line option ahead of regorafenib or fruquintinib in many guidelines. OnCo links it to colorectal cancer, VEGF as a target, trifluridine and tipiracil, bevacizumab and Tae Won Kim, and the result is consistent with the Danish phase 2 trial. Whether the combination should be sequenced before or after fruquintinib, since the two have never been compared, is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
492 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Trifluridine/tipiracil + bevacizumab | 246 | 10.8 months | 0.61 (0.49 to 0.77) | - | link |
| Trifluridine/tipiracil | 246 | 7.5 months |
Shares FRESCO, Tae Won Kim, CORRECT, KRAS G12C-mutant colorectal cancer.
Shares Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer (SUNLIGHT), KRAS G12C-mutant colorectal cancer, Colorectal cancer.
Shares Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer (SUNLIGHT), Trifluridine/tipiracil, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Cytotoxic chemotherapy.
Shares VEGF / VEGFR, Bevacizumab, Cytotoxic chemotherapy, Colorectal cancer.
Shares Trifluridine/tipiracil, Bevacizumab, Cytotoxic chemotherapy, Colorectal cancer.
Shares CORRECT, VEGF / VEGFR, Colorectal cancer.
Shares Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer (SUNLIGHT), VEGF / VEGFR, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Colorectal cancer.
Shares Servier, Trifluridine/tipiracil, Cytotoxic chemotherapy.